NRC FORM 591M PART 1
(06-2010)
10 CFR 2.201

U.S NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Goshen General Hospital **Department of Nuclear Medicine** **200 High Park Avenue** **Goshen, IN 46526** REPORT NUMBER(S) **2010-01**	**U.S. Nuclear Regulatory Commission** **Region III** **2443 Warrenville Road, Suite 210** **Lisle, Illinois 60532-4351**

3. DOCKET NUMBER(S)	4. LICENSEE NUMBER(S)	5. DATE(S) OF INSPECTION
030-14254	**13-18845-01**	November 17, 2010

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☒ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied

_____Non-cited violation(s) were discussed involving the following requirement(s):

☐ 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	**Robert P. Hays**		11/17/10
Branch Chief	**Tamara E. Bloomer**	T E Bloomer	12/6/10

NRC FORM 591 M PART 3
(06-2010)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE	2. NRC/REGIONAL OFFICE
Goshen General Hospital 200 High Park Avenue Goshen, IN 46526 REPORT NUMBER(S) 2010-01	U.S. Nuclear Regulatory Commission Region III 2443 Warrenville Road, Suite 210 Lisle, Illinois 60532-4351

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
03014254	13-18845-01	November 17, 2010

6. INSPECTION PROCEDURES	7. INSPECTION FOCUS AREAS
87131, 87132	03.01-03.07

SUPPLEMENTAL INSPECTION INFORMATION

1.PROGRAM	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
2230	2	John. Lowden, RSO	574-533-2141

X Main Office Inspection — Next Inspection Date: November 2012

☐ Field Office Inspection _____

☐ Temporary Job Site Inspection _____

PROGRAM SCOPE

The licensee was a medical institution with authorization by the license to use any byproduct materials for diagnostic and therapeutic medical procedures under 10 CFR 35.100, 35.200, 35.300, 35.400, HDR afterloader, and Yttrium-90 microspheres. The nuclear medicine department was staffed with 4 nuclear medicine technologists who perform a daily average of 20-25 patient diagnostic studies, M-F, using unit doses received from a Ft. Wayne, IN nuclear pharmacy. The licensee also performs PET studies which average 2-3 PET studies daily, M- F each week. Iodine-131 administrations for thyroid carcinoma therapy averaged one case per month with patient release justification well documented. Prostate seed implant cases average 1 patient per year. Y-90 therapies average 3-4 per month.

The Oncology Department operated a Nucletron HDR for Mammocite and cervical cancer therapies with an average of 10-15 dose fractions administered each week. The licensee's Oncology Department was staffed with one authorized user and two medical physicists who perform treatment setup and double checks of the treatment plan by the authorized user. Source exchanges are performed bimonthly due to the high number of fractions administered each week.

Performance Observations

During the inspection, the licensee's available NMTs (Scott McKee, Greg Miller, Tammy Shively, and John Lowden, RSO, demonstrated/discussed: (1) survey instruments and required surveys; (2) package receipt and check-in procedures; (3) unit dose and safe use procedures; (4) written directives and treatment plans; (5) iodine-131 procedures; (6) Y-90 procedures; (7) security and storage of licensed material; (8) HDR calibrations and output checks; (9) HDR daily checks; (10) emergency tools and procedures; (12) annual refresher training/emergency drills; (13) radiation safety program audit results; and (14) radiation safety committee meeting minutes; and (14) dosimetry and records for CY 2009: 798mr-DDE; 5090mr-finger; and 2010 YTD 2010: 356mr-DDE; 3470mr-finger. High finger dose attributed to PET procedures.